Danaher Co. (NYSE:DHR) Director Sells $172,454.64 in Stock

Danaher Co. (NYSE:DHR) Director Alan G. Spoon sold 708 shares of Danaher stock in a transaction that occurred on Thursday, May 2nd. The stock was sold at an average price of $243.58, for a total value of $172,454.64. Following the completion of the sale, the director now owns 116,202 shares in the company, valued at $28,304,483.16. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Danaher Trading Up 0.6 %

DHR opened at $248.38 on Monday. Danaher Co. has a 52 week low of $182.09 and a 52 week high of $259.00. The company has a quick ratio of 1.51, a current ratio of 1.85 and a debt-to-equity ratio of 0.31. The stock’s fifty day moving average is $248.48 and its two-hundred day moving average is $232.60. The company has a market capitalization of $183.97 billion, a P/E ratio of 42.10, a PEG ratio of 3.82 and a beta of 0.83.

Danaher (NYSE:DHR) last released its quarterly earnings data on Tuesday, April 23rd. The conglomerate reported $1.92 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.72 by $0.20. The firm had revenue of $5.80 billion for the quarter, compared to the consensus estimate of $5.62 billion. Danaher had a net margin of 16.78% and a return on equity of 11.43%. The company’s quarterly revenue was down 2.6% on a year-over-year basis. During the same period last year, the firm earned $2.36 earnings per share. Analysts forecast that Danaher Co. will post 7.63 earnings per share for the current year.

Danaher Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Friday, April 26th. Investors of record on Thursday, March 28th were paid a dividend of $0.27 per share. This represents a $1.08 annualized dividend and a dividend yield of 0.43%. The ex-dividend date of this dividend was Wednesday, March 27th. This is a positive change from Danaher’s previous quarterly dividend of $0.24. Danaher’s payout ratio is 18.31%.

Institutional Trading of Danaher

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Cambridge Investment Research Advisors Inc. lifted its holdings in shares of Danaher by 3.7% during the third quarter. Cambridge Investment Research Advisors Inc. now owns 47,915 shares of the conglomerate’s stock worth $11,888,000 after purchasing an additional 1,705 shares during the period. Robeco Institutional Asset Management B.V. increased its stake in shares of Danaher by 14.7% in the third quarter. Robeco Institutional Asset Management B.V. now owns 78,520 shares of the conglomerate’s stock worth $19,481,000 after acquiring an additional 10,045 shares during the period. Stratos Wealth Partners LTD. raised its holdings in shares of Danaher by 32.9% during the third quarter. Stratos Wealth Partners LTD. now owns 7,412 shares of the conglomerate’s stock worth $1,839,000 after purchasing an additional 1,833 shares during the last quarter. Mn Services Vermogensbeheer B.V. raised its holdings in shares of Danaher by 1.8% during the third quarter. Mn Services Vermogensbeheer B.V. now owns 336,900 shares of the conglomerate’s stock worth $83,585,000 after purchasing an additional 6,000 shares during the last quarter. Finally, York GP Ltd. lifted its position in Danaher by 12.5% during the third quarter. York GP Ltd. now owns 22,500 shares of the conglomerate’s stock valued at $5,582,000 after purchasing an additional 2,500 shares during the period. Hedge funds and other institutional investors own 79.05% of the company’s stock.

Analyst Ratings Changes

A number of research firms have issued reports on DHR. TD Cowen increased their price objective on Danaher from $280.00 to $290.00 and gave the stock a “buy” rating in a report on Wednesday, April 24th. Robert W. Baird increased their target price on shares of Danaher from $259.00 to $271.00 and gave the stock an “outperform” rating in a report on Wednesday, April 24th. KeyCorp lifted their price objective on shares of Danaher from $260.00 to $290.00 and gave the company an “overweight” rating in a research report on Thursday, February 1st. Raymond James increased their price target on Danaher from $240.00 to $270.00 and gave the company an “outperform” rating in a research note on Wednesday, January 31st. Finally, StockNews.com cut shares of Danaher from a “buy” rating to a “hold” rating in a research note on Wednesday, January 31st. Six analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. According to data from MarketBeat.com, Danaher currently has a consensus rating of “Moderate Buy” and an average price target of $267.31.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.